Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par

This article was originally published in The Pink Sheet Daily

Executive Summary

The two parties have terminated a marketing agreement for the anti-emetic based on a change in strategic priorities.
Advertisement

Related Content

Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
Valeant Cesamet Slated To Hit Market In “Next Several Weeks”

Topics

Advertisement
UsernamePublicRestriction

Register

PS063400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel